Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet (扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial-Reference-Cited by-同舟云学术

Treatment of HBV Cirrhosis with Fuzheng Huayu Tablet (扶正化瘀片) and Entecavir: Design of a Randomized, Double-Blind, Parallel and Multicenter Clinical Trial

Published:2020-06-22 Issue:7 Volume:27 Page:509-513
ISSN:1672-0415
Container-title:Chinese Journal of Integrative Medicine
language:en
Short-container-title:Chin. J. Integr. Med.

Author:

Li Zheng-xin,Zhao Zhi-min,Liu Ping,Zheng Qing-shan,Liu Cheng-hai

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Complementary and alternative medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s11655-020-3257-6.pdf

Reference14 articles.

1. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016;10:1–98.

2. Honda K, Seike M, Murakami K. Benefits of nucleos(t)ide analog treatments for hepatitis B virus-related cirrhosis. World J Hepatol 2015;7:2404–2410.

3. Kose S, Tatar B, Gul S, Pala E. The effect of long-term entecavir therapy on liver histopathology in patients with chronic viral hepatitis B. Acta Clin Belg 2016;71:244–249.

4. Wu IC, Lai CL, Han SH, Han KH, Gordon SC, Chao YC, et al. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010;51:1185–1189.

5. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010;52:886–893.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum metabolomics characteristics and fatty-acid-related mechanism of cirrhosis with histological response in chronic hepatitis B;Frontiers in Pharmacology;2023-12-21

2. Convergent application of traditional Chinese medicine and gut microbiota in ameliorate of cirrhosis: a data mining and Mendelian randomization study;Frontiers in Cellular and Infection Microbiology;2023-11-06

3. Syndrome of liver depression and spleen deficiency is a primary TCM syndrome of response to entecavir + FuZheng HuaYu in patients with HBV-related liver fibrosis;Heliyon;2023-11

4. Baseline metabolites could predict responders with hepatitis B virus-related liver fibrosis for entecavir or combined with FuzhengHuayu tablet;World Journal of Hepatology;2023-09-27

5. Therapeutic potential and mechanism of Chinese herbal medicines in treating fibrotic liver disease;Chinese Journal of Natural Medicines;2023-09